Monoclonal Antibody to Heat Shock 60kD Protein 1, Chaperonin (HSPD1)
| Code | Size | Price |
|---|
| MAA822Hu22-20ul | 20ul | £85.00 |
Quantity:
| MAA822Hu22-100ul | 100ul | £156.00 |
Quantity:
| MAA822Hu22-200ul | 200ul | £210.00 |
Quantity:
| MAA822Hu22-1ml | 1ml | £480.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
HSPD1; GROEL; CPN60; HuCHA60; Heat Shock 60kD Protein 1, Chaperonin; Spastic Paraplegia 13,Autosomal Dominant; 60 kDa chaperonin; Mitochondrial matrix protein P1; P60 lymphocyte protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Heat Shock Protein 60
Potency (Clone Number):
C4
Reactivity:
Ra;Ca;Po;Bo;Ga;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL<br/>Immunohistochemistry: 5-30ug/mL<br/>Immunocytochemistry: 5-30ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Heat Shock 60kD Protein 1, Chaperonin (HSPD1) | RPA822Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||